Dupilumab
- Generic Name
- Dupilumab
- Brand Names
- Dupixent
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1190264-60-8
- Unique Ingredient Identifier
- 420K487FSG
- Background
Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways. As an interleukin-4 receptor alpha antagonist, dupilumab inhibits the signaling of pro-inflammatory cytokines, called interleukins (IL), that induce inflammatory and immunological reacti...
- Indication
In the US, dupilumab is indicated for the treatment of patients aged six months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. In Europe and Canada, the drug for this indication is approved for patients aged six years and older. In E...
- Associated Conditions
- Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP), Eosinophilic Esophagitis, Moderate to Severe Asthma, Moderate to Severe Atopic Dermatitis, Oral Steroid-Dependent Asthma (Disorder), Prurigo Nodularis, Severe Asthma, Severe Atopic Dermatitis, Moderate Atopic dermatitis, Moderate Prurigo Nodularis, Severe Prurigo Nodularis
- Associated Therapies
- Add-on therapy, Maintenance therapy
Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD)
- Conditions
- Interventions
- First Posted Date
- 2013-11-08
- Last Posted Date
- 2020-03-18
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 54
- Registration Number
- NCT01979016
Open-label Study of Dupilumab in Patients With Atopic Dermatitis
- First Posted Date
- 2013-09-24
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 2733
- Registration Number
- NCT01949311
- Locations
- 🇵🇱
Regeneron Study Site 5, Warszawa, Mazowieckie, Poland
🇪🇸Regeneron Study Site 4, Barcelona, Spain
🇬🇧Regeneron Study Site 1, London, United Kingdom
An Evaluation of Dupilumab in Patients With Nasal Polyposis And Chronic Symptoms Of Sinusitis
- Conditions
- Interventions
- First Posted Date
- 2013-08-12
- Last Posted Date
- 2017-06-26
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 60
- Registration Number
- NCT01920893
- Locations
- 🇺🇸
Investigational Site Number 840013, Boston, Massachusetts, United States
🇺🇸Investigational Site Number 840014, Rolling Hills Estates, California, United States
🇺🇸Investigational Site Number 840015, Denver, Colorado, United States
Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
- First Posted Date
- 2013-05-22
- Last Posted Date
- 2017-08-28
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 380
- Registration Number
- NCT01859988
An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma
- Conditions
- Interventions
- First Posted Date
- 2013-05-15
- Last Posted Date
- 2017-06-26
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 776
- Registration Number
- NCT01854047
- Locations
- 🇯🇵
Investigational Site Number 392024, Sakai-Shi, Japan
🇯🇵Investigational Site Number 392003, Toride-Shi, Japan
🇯🇵Investigational Site Number 392035, Yokohama-Shi, Japan
Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD)
- Conditions
- Interventions
- First Posted Date
- 2012-07-12
- Last Posted Date
- 2017-10-13
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 31
- Registration Number
- NCT01639040
Study of Dupilumab in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis
- First Posted Date
- 2012-03-08
- Last Posted Date
- 2018-08-10
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 109
- Registration Number
- NCT01548404
Safety and Tolerability of Dupilumab in Participants With Moderate to Severe Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2011-06-30
- Last Posted Date
- 2020-02-26
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 37
- Registration Number
- NCT01385657
Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma
- First Posted Date
- 2011-03-11
- Last Posted Date
- 2017-06-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 104
- Registration Number
- NCT01312961
- Locations
- 🇺🇸
Investigational Site Number 840003, Minneapolis, Minnesota, United States
🇺🇸Investigational Site Number 840006, Saint Louis, Missouri, United States
🇺🇸Investigational Site Number 840047, Anaheim, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.